Both Viking Therapeutics Inc. (NASDAQ:VKTX) and SELLAS Life Sciences Group Inc. (NASDAQ:SLS) are Biotechnology companies, competing one another. We will compare their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics Inc.	N/A	0.00	22.06M	-0.45	0.00
SELLAS Life Sciences Group Inc.	N/A	0.00	41.25M	-4.96	0.00

In table 1 we can see Viking Therapeutics Inc. and SELLAS Life Sciences Group Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 shows us the net margins, return on assets and return on equity of both companies.

	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics Inc.	0.00%	-15.8%	-15.1%
SELLAS Life Sciences Group Inc.	0.00%	-625.6%	-76.1%

Volatility and Risk

Viking Therapeutics Inc. has a beta of 2.74 and its 174.00% more volatile than Standard and Poor’s 500. SELLAS Life Sciences Group Inc.’s 70.00% more volatile than Standard and Poor’s 500 volatility due to the stock’s 1.7 beta.

Liquidity

Viking Therapeutics Inc.’s Current Ratio and Quick Ratio are 64.6 and 64.6 respectively. The Current Ratio and Quick Ratio of its competitor SELLAS Life Sciences Group Inc. are 1.5 and 1.5 respectively. Viking Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to SELLAS Life Sciences Group Inc.

Analyst Recommendations

The Ratings and Recommendations for Viking Therapeutics Inc. and SELLAS Life Sciences Group Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Viking Therapeutics Inc.	0	0	4	3.00
SELLAS Life Sciences Group Inc.	0	0	1	3.00

The average price target of Viking Therapeutics Inc. is $23.4, with potential upside of 150.27%. Competitively SELLAS Life Sciences Group Inc. has a consensus price target of $4.5, with potential upside of 332.69%. Based on the data delivered earlier, SELLAS Life Sciences Group Inc. is looking more favorable than Viking Therapeutics Inc., analysts view.

Institutional & Insider Ownership

Roughly 68% of Viking Therapeutics Inc. shares are owned by institutional investors while 31.1% of SELLAS Life Sciences Group Inc. are owned by institutional investors. 11% are Viking Therapeutics Inc.’s share owned by insiders. Comparatively, 1.9% are SELLAS Life Sciences Group Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Viking Therapeutics Inc.	1.05%	6.62%	-23.68%	-27.98%	39.2%	13.73%
SELLAS Life Sciences Group Inc.	-1.41%	-4.11%	-17.65%	33.6%	-72%	13.82%

For the past year Viking Therapeutics Inc. was less bullish than SELLAS Life Sciences Group Inc.

Summary

Viking Therapeutics Inc. beats SELLAS Life Sciences Group Inc. on 5 of the 7 factors.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. The company also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder. In addition, it develops VK0612, an orally available drug candidate for the treatment of type 2 diabetes; small molecule agonists of the erythropoietin receptor for the treatment of anemia; and tissue-selective inhibitors of diacylglycerol acyltransferase-1 for the treatment of obesity and dyslipidemia. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

SELLAS Life Sciences Group, Inc., a development-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S, a cancer immunotherapeutic agent for the treatment of hematologic cancers and solid tumor indications, including acute myeloid leukemia, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, immune combo, and chronic myelogenous leukemia. It also develops NEUVAX, which is in Phase II clinical trial for the treatment of breast cancer; and Anagrelide controlled release, which has completed various clinical trials for the treatment of thrombocythemia. The company has collaboration and license agreements with Memorial Sloan Kettering Cancer Center, Advaxis Immunotherapies, Merck & Co., Inc., National Cancer Institute, and the University of Texas M.D. Anderson Cancer Center. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.